Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Common Equity (2023 - 2025)

Historic Common Equity for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to $231.1 million.

  • Tonix Pharmaceuticals Holding's Common Equity rose 21146.73% to $231.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $231.1 million, marking a year-over-year increase of 21146.73%. This contributed to the annual value of $139.6 million for FY2024, which is 3225.11% up from last year.
  • Tonix Pharmaceuticals Holding's Common Equity amounted to $231.1 million in Q3 2025, which was up 21146.73% from $168.0 million recorded in Q2 2025.
  • Over the past 5 years, Tonix Pharmaceuticals Holding's Common Equity peaked at $231.1 million during Q3 2025, and registered a low of $42.1 million during Q2 2024.
  • For the 3-year period, Tonix Pharmaceuticals Holding's Common Equity averaged around $134.2 million, with its median value being $139.6 million (2024).
  • As far as peak fluctuations go, Tonix Pharmaceuticals Holding's Common Equity crashed by 7002.56% in 2024, and later surged by 29902.38% in 2025.
  • Quarter analysis of 3 years shows Tonix Pharmaceuticals Holding's Common Equity stood at $105.5 million in 2023, then soared by 32.25% to $139.6 million in 2024, then skyrocketed by 65.63% to $231.1 million in 2025.
  • Its Common Equity was $231.1 million in Q3 2025, compared to $168.0 million in Q2 2025 and $180.4 million in Q1 2025.